Tocilizumab (Roche) is an IL-6 receptor antagonist that was approved by the FDA for the management of severe CRS and has demonstrated a high response rate in patients with sCRS.6,7,9,29,30 Siltuximab (Janssen) binds to soluble IL-6, but has not been studied as first-line therapy for CRS and is not currently approved for this indication. The gene discussed is IL6; the disease is congenital rubella syndrome.